Preliminary Research Findings MP1

 

 

Here is the preliminary research findings on Dr. Keller's MP1 medication.

 

MP1 is a patented combination of off patent drugs together with natural

substances that thwarts the virus by decreasing cell activation and

blocking viral docking to the CD4 %T cell; 2 inhibiting enzyme activity required

for viral up regulation through tat and tar, not by attacking viral

enzymesi but by changing the internal milieu(pH) of the cytosol and 3; by

interfering with HIV integration into the genome.

 

Our research to date suggests;

 

1) there is no viral resistance invitro nor in vivo to date and given

the mechanism of action, it is difficult to create a scenario even sub

adequate compliance where viral resistance would occur.

 

2) after 5 passages of the virus through MP1, it is incapable of

infecting fresh T cells.

 

3) nine patients are currently on MPi using the FDA sanctioned doctrine

of OLP. In the six who are evaluable at the 12 weeks, the average log

decrease of HIV is 4.43, the average increase in t cell is 12% which is early

compared to the HAART trail at 12 weeks and of particular note is a 78%

improvement in liver function (ALT) in the five of six patients who had significant

liver inflammation dfue to Hep C and/or HAART

 

4) once funding is obtained (approx. 750,000) dollars for phase I  and

pk studies, the cost of this drug to the end consumer will be between a

dollar to 1.50 per day and will not have the numerous complications associated

with HAART

 

Sincerely,

 

Benjamin D. Sanders R.Ph.D. Int.

Doctoral Pharmacist Intern

Bachelorret Computational Biochemist

(954) 462-2289 - home

bensanders76@yahoo.com

bsanders@mymail.indstate.edu